|
|
|
|
|
|
Free Newsletters
Archive
My eNewsletters
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Login
Become a Member
Discussion Forums
FAQ
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
Maxygen, Inc. (MAXY) (JOBS) Announces New CEO
9/29/2009
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Maxygen, Inc. (Nasdaq:MAXY - News) announced today that James Sulat, who currently serves as a director of the company, has been appointed to serve as Maxygen’s Chief Executive Officer, effective October 1, 2009. Mr. Sulat will replace Russell Howard, who has served as Maxygen’s Chief Executive Officer and as a director since June 1998. Dr. Howard will be leaving his positions as an officer and director of Maxygen on September 30, 2009. Larry Briscoe, Maxygen’s Chief Financial Officer, will also be departing the company on September 30, 2009. These management changes are being made as part of Maxygen’s restructuring in connection with the recently consummated joint venture transaction with Astellas Pharma Inc. Dr. Howard and Mr. Briscoe will each enter into consulting agreements with Maxygen and remain available to advise the company on various matters.
In addition to his role as Chief Executive Officer, Mr. Sulat will also assume the role of Chief Financial Officer and will continue to serve on Maxygen’s Board of Directors.
“Jim brings the right skill set to lead Maxygen as we move from a focus on drug research and development to a focus on managing Maxygen’s assets to maximize the return to our stockholders over the next few years,” said Isaac Stein, Maxygen’s Executive Chairman of the Board.
“The Board and employees of Maxygen are extremely grateful to Russell and Larry for their leadership and contributions over the past years,” added Mr. Stein. “We also appreciate their support in assuring continuity and the smooth transition of Maxygen’s new leadership.”
About Maxygen
Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs through both internal development and external collaborations and other arrangements. Maxygen uses its proprietary DNA shuffling technology and extensive protein modification expertise to pursue the creation of biosuperior proteins. www.maxygen.com
Contact:
Maxygen, Inc.
Linda Chrisman, 650-298-5351
linda.chrisman@maxygen.com
|
|
|
|
|
|
|
|
|
|
|
|